Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Moraxellaceae Stories

2013-10-15 21:02:43

A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings, UT Southwestern Medical Center researchers report. The technology and new approach offer potential promise against the growing problem of antibiotic resistance, the researchers said. The pathogen (germ) – called Acinetobacter – can cause infections from pneumonia to serious blood or wound...

2013-08-14 08:29:05

-- Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate -- ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and six months ended June 30, 2013 and provided an operational update. The...

2013-07-24 11:16:36

The story begins with a problem - a virulent strain of a drug-resistant bacteria that was imported with the wounded from Afghanistan and spread through the United States. In cancer wards and other places where people with impaired immune systems were treated, this infection caused by the gram-negative bacterium, Acinetobacter baumannii, was particularly dangerous and it evaded the wiles of most known antibiotics. Infections caused by such gram-negative pathogens (Escherichia coli, Klebsiella...

2013-04-16 08:28:22

-- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md., April 16, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational highlights. Operational Highlights: Expanding Infectious Disease Portfolio C....

2013-02-21 12:26:42

OTTAWA, Feb. 21, 2013 /CNW/ - Sequel Naturals Ltd. is voluntarily recalling three lots of its natural health product "Vega One French Vanilla" in various sizes (see table below) after testing conducted by Health Canada identified bacteria that could pose a risk to consumers with weakened immune systems. The testing found the presence of Klebsiella species (K. oxytoca), Citrobacter braakii, Cronobacter sakazakii group, Enterobacter cloacae complex, Acinetobacter species (A. baumannii...

2012-11-14 16:26:05

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, today reported financial results for the three and nine months ended September 30, 2012 and summarized operational highlights. Operational Highlights Completed Successful Capital Raise Increased cash position with net proceeds of $10.1 million from the sale of approximately 6.8 million shares of common...

2012-11-08 08:35:45

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- In a presentation at IDWeek 2012, and reported in Medscape Medical News, Deverick Anderson, MD, MPH, from the Duke Infection Control Outreach Network, issued an announcement that in a multicenter, prospective study, Tru-D SmartUVC was effective in decreasing levels of vancomycin-resistant enterococci (VRE), Clostridium difficile, and Acinetobacter both by direct line-of-sight and indirect (reflected) illumination. "The environment plays a role in the...

2012-10-18 11:22:13

OAKLAND, Calif., Oct. 18, 2012 /PRNewswire-USNewswire/ -- A new study published in the November issue of Infection Control and Hospital Epidemiology (ICHE), the journal of the Society for Healthcare Epidemiology of America (SHEA), finds for the first time that improved hydrogen peroxide, the active ingredient found in products such as Clorox Healthcare(TM) Hydrogen Peroxide Cleaner Disinfectants, had a greater log-reduction of organisms at a one-minute contact time than standard hydrogen...

2012-09-18 02:26:43

ANN ARBOR, Mich., Sept. 18, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections. Many strains of Acinetobacter are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those...

2012-09-09 23:01:32

Synedgen´s active ingredient disrupts bacterial biofilms. (PRWEB) September 09, 2012 Synedgen VP of Research, Stacy Townsend PhD, will present research showcasing Synedgen´s unique technology to control wound biofilms and inflammation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the world´s premier international conference on antimicrobial agents and infectious diseases in San Francisco on September 11. The presentation entitled,...